These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12446026)

  • 1. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.
    Killestein J; Hintzen RQ; Uitdehaag BM; Baars PA; Roos MT; van Lier RA; Polman CH
    J Neuroimmunol; 2002 Dec; 133(1-2):217-24. PubMed ID: 12446026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.
    Noronha A; Toscas A; Jensen MA
    J Neuroimmunol; 1993 Jul; 46(1-2):145-53. PubMed ID: 8360326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients.
    Hartrich L; Weinstock-Guttman B; Hall D; Badgett D; Baier M; Patrick K; Feichter J; Hong J; Ramanathan M
    J Neuroimmunol; 2003 Jun; 139(1-2):84-92. PubMed ID: 12799025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma induces T lymphocyte proliferation in multiple sclerosis via a Ca(2+)-dependent mechanism.
    Martino G; Moiola L; Brambilla E; Clementi E; Comi G; Grimaldi LM
    J Neuroimmunol; 1995 Nov; 62(2):169-76. PubMed ID: 7499505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells.
    Rep MH; Hintzen RQ; Polman CH; van Lier RA
    J Neuroimmunol; 1996 Jul; 67(2):111-8. PubMed ID: 8765333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta.
    Rudick RA; Carpenter CS; Cookfair DL; Tuohy VK; Ransohoff RM
    Neurology; 1993 Oct; 43(10):2080-7. PubMed ID: 8105424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
    Schmidt S; Moric E; Schmidt M; Sastre M; Feinstein DL; Heneka MT
    J Leukoc Biol; 2004 Mar; 75(3):478-85. PubMed ID: 14657213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta.
    Hallal-Longo DE; Mirandola SR; Oliveira EC; Farias AS; Pereira FG; Metze IL; Brandão CO; Ruocco HH; Damasceno BP; Santos LM
    J Interferon Cytokine Res; 2007 Oct; 27(10):865-73. PubMed ID: 17970696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation.
    Huang H; Ito K; Dangond F; Dhib-Jalbut S
    J Neuroimmunol; 2013 May; 258(1-2):27-31. PubMed ID: 23489746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vivo and vitro effects of interferon-alpha 2b on functional activity of T-lymphocytes from patients with rheumatoid arthritis].
    Iarilina AA; Nikonova MF; Litvina MM; Balabanova RM; Iarilin AA
    Ter Arkh; 2000; 72(5):9-17. PubMed ID: 11109610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins as immunomodulators: comparison with interferon-beta 1b in MS.
    Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier BC; Niederwieser G; Hartung HP; Archelos JJ
    Neurology; 2002 Oct; 59(7):990-7. PubMed ID: 12370451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
    Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
    J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Tanasescu R; Midgley A; Robins RA; Constantinescu CS
    Acta Neurol Scand; 2017 Sep; 136(3):233-238. PubMed ID: 27918083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls.
    Vanderlocht J; Hendriks JJ; Venken K; Stinissen P; Hellings N
    J Neuroimmunol; 2006 Aug; 177(1-2):189-200. PubMed ID: 16797728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta induces T-helper 2 immune deviation in MS.
    Kozovska ME; Hong J; Zang YC; Li S; Rivera VM; Killian JM; Zhang JZ
    Neurology; 1999 Nov; 53(8):1692-7. PubMed ID: 10563614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.